Literature DB >> 25140794

Souroubea sympetala (Marcgraviaceae): a medicinal plant that exerts anxiolysis through interaction with the GABAA benzodiazepine receptor.

Martha Mullally1, Christian Cayer, Kari Kramp, Marco Otárola Rojas, Pablo Sanchez Vindas, Mario Garcia, Luis Poveda Alvarez, Tony Durst, Zul Merali, Vance L Trudeau, John T Arnason.   

Abstract

The mode of action of the anxiolytic medicinal plant Souroubea sympetala was investigated to test the hypothesis that extracts and the active principle act at the pharmacologically important GABAA-benzodiazepine (GABAA-BZD) receptor. Leaf extracts prepared by ethyl acetate extraction or supercritical extraction, previously determined to have 5.54 mg/g and 6.78 mg/g of the active principle, betulinic acid, respectively, reduced behavioural parameters associated with anxiety in a rat model. When animals were pretreated with the GABAA-BZD receptor antagonist flumazenil, followed by the plant extracts, or a more soluble derivative of the active principle, the methyl ester of betulinic acid (MeBA), flumazenil eliminated the anxiety-reducing effect of plant extracts and MeBA, demonstrating that S. sympetala acts via an agonist action on the GABAA-BZD receptor. An in vitro GABAA-BZD competitive receptor binding assay also demonstrated that S. sympetala extracts have an affinity for the GABAA-BZD receptor, with an EC50 value of 123 μg/mL (EtOAc leaf extract) and 154 μg/mL (supercritical CO2 extract). These experiments indicate that S. sympetala acts at the GABAA-BZD receptor to elicit anxiolysis.

Entities:  

Keywords:  acide bétulinique; anxiety; anxiété; betulinic acid; ester de méthyle d’acide bétulinique; methyl ester of betulinic acid; natural health product; pharmacologie; pharmacology; produit de santé naturel

Mesh:

Substances:

Year:  2014        PMID: 25140794     DOI: 10.1139/cjpp-2014-0213

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

Review 1.  New Botanical Anxiolytics for Use in Companion Animals and Humans.

Authors:  Rui Liu; Fida Ahmed; Christian Cayer; Martha Mullally; Ana Francis Carballo; Marco Otarola Rojas; Mario Garcia; John Baker; Aleksandar Masic; Pablo E Sanchez; Luis Poveda; Zul Merali; Tony Durst; John T Arnason
Journal:  AAPS J       Date:  2017-09-11       Impact factor: 4.009

2.  Safety evaluation of a new anxiolytic product containing botanicals Souroubea spp. and Platanus spp. in dogs.

Authors:  Aleksandar Masic; Rui Liu; Kristen Simkus; Jeff Wilson; John Baker; Pablo Sanchez; Ammar Saleem; Cory C Harris; Tony Durst; John T Arnason
Journal:  Can J Vet Res       Date:  2018-01       Impact factor: 1.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.